Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS) has announced a 5-year partnership with Reese Witherspoon as the global brand ambassador for Biossance®, a rapidly growing clean skincare brand. This collaboration aims to enhance consumer awareness and education surrounding clean beauty. Witherspoon will create engaging content and limited-edition products, focusing on sustainability and skincare efficacy. Biossance emphasizes a commitment to high-performance, clean ingredients and is recognized for its leadership in the clean beauty movement. This partnership is expected to drive growth and consumer engagement in the sustainable skincare market.
Amyris (Nasdaq: AMRS) announced participation in the Cowen's 2nd Annual Consumer Platforms for the Next Generation Summit on April 6, 2021, at 9:30 am ET. The event will include a fireside chat to discuss the company's advancements in synthetic biotechnology for the Clean Health and Beauty markets. A live webcast and replay will be available on their Investor Relations website. Amyris is a leader in sustainable ingredients, serving over 200 million consumers through its brands like Biossance and Pipette.
Amyris, Inc. (Nasdaq: AMRS) will host its third webinar in a virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology" on April 22, 2021, at 1:00 pm ET. This session will cover the roadmap for Amyris's ingredients portfolio and include a Q&A session. Key topics include valuation of molecules, long-term partner collaborations, and insights into recent strategic transactions. The webinar will feature the CEO of Minerva Foods. Interested participants can join via a live audio webcast or call.
Amyris, Inc. (Nasdaq: AMRS) has closed a significant agreement with DSM Nutritional Products Ltd. for exclusive rights to supply its flavor and fragrance ingredients, valued at over $500 million. This amount includes an upfront payment, earn-out payments over three years, and a 15-year manufacturing agreement. The collaboration aims to enhance the development of clean, sustainable chemistry in the industry. Amyris expects this transaction and its first-quarter performance to contribute nearly half of its total anticipated revenue for 2021.
Amyris, Inc. (Nasdaq: AMRS) announced a significant achievement in producing Cannabigerol (CBG) from fermentation for skincare applications. This production run marks the largest industrial-scale fermentation-based CBG production to date, utilizing 225,000 fermenters at its Spain facility. Amyris anticipates selling one million retail units of CBG over the next year. The CBG molecule outperforms CBD in clinical studies for skin care applications. CEO John Melo highlighted their market leadership in sustainable ingredients and upcoming strategic transactions expected to enhance company performance.
Amyris, Inc. (Nasdaq: AMRS) announced a partnership with Minerva Foods to develop sustainable animal protein molecules. Funded by Minerva, Amyris will create new molecules, including natural preservatives that enhance meat shelf-life while reducing CO2 emissions. The commercialization of the first product is expected within 18 months. This collaboration is anticipated to generate several million dollars in revenue this year and contributes to Amyris's long-term growth. Definitive agreements are expected to be signed in the coming weeks, with closure anticipated in Q2 2021.
Amyris, Inc. (Nasdaq: AMRS) announced a partnership with Minerva Foods to develop sustainable molecules for animal protein production. Funded by Minerva, Amyris aims to create solutions for meat preservation that enhance shelf-life and reduce CO2 emissions. The first commercialization is anticipated within 18 months. This partnership is expected to generate several million dollars in revenue for Amyris this year, furthering its growth into the fermentation-based protein market. Definitive agreements are to be finalized by Q2 2021.
Amyris, a leader in sustainable biotechnology, will participate in a fireside chat at the 33rd Annual Roth Conference on March 17, 2021, at 1:00 pm ET. This event will be hosted virtually, with a live webcast available on the company's Investor Relations website. Amyris specializes in developing clean and natural ingredients for health and beauty markets through a proprietary synthetic biology platform, impacting over 200 million consumers globally.
Amyris, Inc. (Nasdaq: AMRS) reported strong financial results for Q4 and the full year of 2020. Q4 sales revenue reached $80 million, nearly doubling year-over-year, with a significant 71% growth in Product revenue. The Consumer segment saw a remarkable 161% increase, equating to the entire revenue of 2019 in just Q4. The company completed a $200 million equity financing and reduced debt to $171 million. For 2021, Amyris expects underlying total revenue of about $240 million, with reported revenue around $400 million, projecting continued positive adjusted EBITDA.
